TheEdgeResearch
Home / Stocks / KNBIF

Kane Biotech Inc. (KNBIF)

OTC Healthcare Biotechnology
$0.02 ▲ +2.22%
Market Cap
$3.8M
Sector
Healthcare
Industry
Biotechnology
Beta
0.31
52-Wk Range
0.01038-0.036
CEO
Robert Huizinga
Country
CA
Currency
USD

Kane Biotech Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in Winnipeg, MB, CA. The stock last traded at $0.02, up 2.22% on the session, giving a market capitalisation of $3.8M. On trailing twelve-month figures it carries a trailing P/E of -1.98, a net margin of -3785.9%. Its beta of 0.31 implies it has historically moved less than the broad market.

Valuation & profitability (TTM)
P/E
-1.98
Price / Sales
87.52
Price / Book
-3.21
EV / EBITDA
-2.66
Gross margin
-390.5%
Operating margin
-4487.6%
Net margin
-3785.9%
Return on equity
Debt / equity
-1.35
Current ratio
0.45
Dividend yield
0.0%
Payout ratio
0.0%
Company profile
Exchange
Other OTC
Employees
20
IPO date
2007-08-07
Headquarters
Winnipeg, MB, CA
About Kane Biotech Inc.

Kane Biotech Inc. is a biotechnology firm specializing in the research, development, and global commercialization of innovative technologies and products focused on preventing and eradicating microbial biofilms. The company's diverse product lineup includes pet dental care solutions under the StrixNB and bluestem brands, as well as DispersinB for treating wounds in both animals and humans. They also manufacture Alosera shampoos for dogs, cats, and horses, and Aledex coatings for medical devices. Additionally, Kane Biotech provides DermaKB products for scalp health, Coactiv+ for wound management, and other offerings such as goldstem, silkstem, and DermaKB Biofilm. Founded in 2001, Kane Biotech Inc. is headquartered in Winnipeg, Canada.

Comparable companies

Kane Biotech Inc. is most often compared with the following Healthcare names:

BIXTBUDZBVAXFBZYRFAMDFGLWLFMYNDFPMEDFTHERTXTM
More research on KNBIF
KNBIF technical analysis KNBIF TheEdge Score Compare against peers
Open full interactive analysis & DCF →